Posted: 11th December 2017
Abingdon Health Ltd (“Abingdon”) is pleased to announce the completion of a funding round raising £1.1m from current shareholders. The investment will be applied to working capital for the continued extension of the company’s lateral flow device product set and associated state-of-the-art reader systems. This includes Seralite®, our rapid test for the diagnosis and management of patients with myeloma.
Abingdon CEO, Chris Yates, commented “We are delighted to secure this funding and we thank our shareholders for their continued support. At Abingdon, we have created a growing immunodiagnostics-based rapid-test company and this additional investment will allow us to continue to develop and sell our portfolio of products and services”.
About Abingdon Health
Abingdon develop and manufacture lateral flow assays and readers under the Abingdon brand specialising in the area of multiple myeloma. Abingdon also offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon take projects from initial concept through to routine and large-scale manufacturing. Abingdon’s patented lateral flow reader, the ADxLR5®, is CE marked and FDA registered and can be fully customised to meet the needs of clients looking for a quantitative solution for a lateral flow assay.
© Abingdon Health 2018